Trial Profile
Phase 1 Multiple Ascending Dose Study of Elotuzumab (BMS-901608) in Combination With Lenalidomide/Low-dose Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma in Japan.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Elotuzumab (Primary) ; Dexamethasone; Lenalidomide
- Indications Multiple myeloma
- Focus Adverse reactions
- Sponsors Bristol-Myers Squibb
- 12 Jul 2020 Results (n=420) from NCT01241292, NCT0139396415, NCT01441973,NCT022728038, NCT0123979718, evaluating PPK analysis of elotuzumab (including data from Japanese patients n=77) with multiple myeloma, published in the Journal of Clinical Pharmacology
- 19 Apr 2017 Status changed from active, no longer recruiting to completed.
- 06 Jul 2015 Planned End Date changed from 1 Aug 2015 to 1 Aug 2016 as per ClinicalTrials.gov record.